Oncotelic Therapeutics, Inc. (OTLC) Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Oncotelic Therapeutics, Inc. OTC:OTLC Healthcare · Biotechnology
Mkt Cap $7.5M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
Oncotelic announced publication of a peer-reviewed Biomedicines study using its AI-driven PDAOAI platform to identify a four-gene prognostic signature (FKBP1A, EIF4E, RRAGC, PPARGC1A) in hepatocellular carcinoma.
The signature was independently validated in a Japanese HCC cohort of 203 patients and defines patient stratification for planned clinical trials of Sapu003, an intravenous formulation of everolimus.
The company also highlighted its patent-pending PLA algorithm, plans to scale the platform to roughly 100 billion biological vectors, and its free BIO REBOOT program offering selected projects startup funding and development support.
• 6d ago AI analysis › Press Release
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery
Oncotelic Therapeutics announced that Chief Business Officer Saran Saund will deliver the opening Day 2 keynote at the 22nd Drug Discovery Strategic Summit on October 22, 2026.
The presentation will cover partition and aggregation as an organizing principle for AI-enabled discovery, tying it to the company's PDAOAI platform, international IP strategy, Fastbot/Membot researcher access, and a planned expansion toward 100 billion biological vectors.
The release contains no new financial, clinical, or regulatory data; it is a visibility event for the company's AI drug-discovery platform.
• 12d ago AI analysis › Press Release ⚠ 2
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Oncotelic Therapeutics announced that its PDAOAI AI drug discovery platform is opening a free collaboration initiative called BIO REBOOT, inviting scientists, AI developers and biotech founders to submit research questions and drug discovery ideas.
Selected projects may be considered for startup funding and Oncotelic development support, subject to scientific review and available resources. The announcement accompanies keynote presentations by executives at the Drug Discovery 2026 conference, including a hepatocellular carcinoma case study where PDAOAI identified a candidate four-gene mTOR signature from 4.4 million abstracts.
PDAOAI is built on an index of 29 million PubMed abstracts and is a visibility play for the company's AI platform rather than a clinical or financial catalyst; funding terms are non-committal.
• 27d ago AI analysis › Press Release
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
Oncotelic Therapeutics (OTLC) announced that CEO Dr. Vuong Trieu will present at the OTCQB Virtual Investor Conference on August 6, 2026. The presentation is scheduled for 2:30 PM ET and will include a live Q&A session for investors.
Recent highlights include the advancement of the Phase 1b IV Everolimus program to the next dose cohort. The company also noted the establishment of clinical-stage manufacturing and validation of its Deciparticle delivery platform.
• 2mo ago AI analysis › Press Release
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
Oncotelic Therapeutics and Sapu Nano announced a peer-reviewed publication in Biomedicines validating the preclinical translational package for Sapu003, an intravenous formulation of everolimus.
The study demonstrates favorable pharmacokinetics, reduced gastrointestinal accumulation compared to oral administration, and successful reproducible cGMP manufacturing of the Deciparticle™ formulation.
These findings support the ongoing Phase 1b SP-03-B101 clinical trial evaluating Sapu003 in patients with advanced mTOR-sensitive solid tumors.
• 3mo ago AI analysis › Press Release
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Oncotelic’s subsidiary Sapu Nano completed the initial three-patient safety cohort of its Phase 1b SP-03-B101 trial for Sapu003, an intravenous everolimus formulation.
The independent Safety Review Committee observed no dose-limiting toxicities and recommended advancing to the next dose level.
The company is expanding the trial into Europe and highlighted a peer-reviewed publication validating its Deciparticle nanomedicine platform.
• 3mo ago AI analysis › Press Release
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Oncotelic and Sapu Nano announced a peer-reviewed publication in the International Journal of Molecular Sciences validating the Deciparticle platform and the Sapu003 intravenous everolimus formulation.
The paper details a scalable cGMP manufacturing process and favorable stability profile for Sapu003, which is currently in a Phase 1b trial for advanced mTOR-sensitive solid tumors.
CEO Vuong Trieu noted that the independent review validates the platform's potential to enable intravenous delivery of poorly water-soluble compounds beyond just everolimus.
• 4mo ago AI analysis › Press Release
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Oncotelic Therapeutics launched its AI-powered GMP manufacturing services platform at the BIO International Convention, integrating its proprietary PDAOAI architecture with intelligent robotics from partner TechForce Robotics.
The new platform targets pharmaceutical and biotechnology companies with capabilities for electronic batch records, AI-assisted documentation, and automated quality management.
Separately, the company highlighted its 45% ownership of the GMP Bio joint venture and the ongoing Phase 1b clinical evaluation of its SAPU003 program.
• 4mo ago AI analysis › Press Release ⚠ 3
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
Oncotelic completed Phase 2 objectives in its joint initiative with TechForce Robotics to advance an AI-powered GMP manufacturing platform at its SAPU Bio joint venture.
The deployment expands the proprietary PDAOAI platform across sterile manufacturing operations, including electronic batch records and autonomous materials movement.
Management plans to demonstrate the integrated robotics platform at the BIO International Convention 2026 to attract manufacturing partners and biotech customers.
• 4mo ago AI analysis › Press Release ⚠ 2
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
Oncotelic Therapeutics (OTLC) is featured in an Audio Press Release distributed by NetworkNewsAudio discussing the exploration of nanoparticle and targeted drug-delivery technologies in oncology.
The release highlights the company’s Deciparticle platform and lead candidate Sapu003, focusing on improving the clinical utility of established therapies through advanced nanotechnology-enabled delivery systems.
It also notes the company’s intellectual property portfolio, including over 500 patent applications filed by CEO Dr. Vuong Trieu, and its 45% interest in joint venture GMP Bio.
• 4mo ago AI analysis › Press Release ⚠ 3
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
Oncotelic Therapeutics highlighted its strategy of using nanotechnology-driven delivery systems to enhance existing oncology therapies, rather than solely pursuing new compound discovery.
The company referenced its Sapu003 asset and Deciparticle platform as key components of this approach, aiming to improve pharmacokinetics and tumor accumulation.
CEO Dr. Vuong Trieu’s extensive patent portfolio (39 issued US patents) and the company’s 45% stake in joint venture GMP Bio were cited as strategic assets supporting this pipeline.
• 4mo ago AI analysis › Press Release ⚠ 3
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
BioMedWire published a paid editorial focusing primarily on Oncotelic Therapeutics (OTLC) and its drug-delivery platforms.
CytoDyn (CYDY) is mentioned briefly as one of several companies developing scalable biotechnology platforms.
The article notes that CytoDyn has enrolled the first participant in its Expanded Access Program for leronlimab in triple-negative breast cancer patients.
• 4mo ago AI analysis › Press Release
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
Oncotelic Therapeutics (OTLC) announced the expansion of its Sapu003 Phase 1b clinical program beyond Australia into Europe.
The company appointed Global Clinical Trials (GCT) as the lead contract research organization to support the international execution of Study SP-03-B101.
This move establishes the regulatory and operational infrastructure necessary for future multinational Phase 3 development of the intravenous everolimus formulation.
• 4mo ago AI analysis › Press Release ⚠ 3
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
Oncotelic Therapeutics announced a paid editorial placement in BioMedWire highlighting its nanotechnology-enabled drug delivery strategy.
The article describes the company's Sapu003 program and Deciparticle platform as part of a broader industry trend toward advanced delivery systems.
It notes that CEO Dr. Vuong Trieu holds 39 issued U.S. patents and that Oncotelic owns 45% of joint venture GMP Bio.
• 4mo ago AI analysis › Press Release ⚠ 2
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
TechForce Robotics, a subsidiary of Nightfood Holdings (NGTF), announced the successful completion of Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTLC).
The milestone was marked by the initial deployment of LIM-E, an autonomous laboratory support robot, validating the company's expansion into pharmaceutical automation.
This deployment extends TechForce's AI-enhanced robotics platform beyond hospitality into high-value life sciences workflows, supporting its Robotics-as-a-Service (RaaS) model.
• 5mo ago AI analysis › Press Release
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
Oncotelic Therapeutics (OTLC) announced that CEO Vuong Trieu will present its Deciparticle nanomedicine platform at BIO International Convention 2026 in San Diego.
The presentation highlights progress on Sapu006 (IV docetaxel) entering Phase 1b and Sapu003 (IV everolimus) in global Phase 1b trials, alongside the integration of AI via the PDAOAI platform.
The company emphasized the platform’s ability to formulate water-insoluble therapeutics into sub-20nm particles, aiming to reduce toxicity and improve manufacturability for oncology applications.
• 5mo ago AI analysis › Press Release
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
Oncotelic Therapeutics filed its Q1 2026 10-Q and issued a strategic update highlighting progress in oncology, AI-enabled drug development, and drug delivery platforms.
The company confirmed that the fair value of its 45% stake in GMP Biotechnology Limited remains at approximately $388 million, supported by an independent third-party valuation.
Management emphasized capital-efficient advancement of programs including Sapu003, Sapu006, and the nose-to-brain delivery platform, without disclosing specific Q1 revenue or cash position figures in this release.
• 5mo ago AI analysis › Press Release ⚠ 2
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
NetworkNewsAudio released an audio press release summarizing Oncotelic Therapeutics' focus on bypassing blood-brain barrier limitations.
The release highlights a previously announced strategic monetization of the N2B delivery system to Lunai Bioworks for biodefense and Alzheimer's applications.
No new financial results, clinical data, or corporate actions were disclosed in this third-party distribution.
• 5mo ago AI analysis › Press Release
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
globenewswire.com • 5mo ago Press Release
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
Sapu Nano and Oncotelic announced the first patient dosed in a Phase 1b trial of Sapu003, an intravenous formulation of everolimus for advanced mTOR-sensitive solid tumors.
The open-label, dose-escalation study will evaluate safety and pharmacokinetics in two cohorts: HR+/HER2- breast cancer (combination therapy) and RCC, NETs, TSC, or HCC (monotherapy).
Sapu003 aims to improve exposure control and reduce toxicity compared to oral everolimus, with planned dose levels of 3.5 to 10 mg/m².
• 5mo ago AI analysis › Press Release
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
globenewswire.com • 5mo ago Press Release ⚠ 1
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
Oncotelic Therapeutics closed a strategic asset transfer with Lunai Bioworks, granting worldwide rights to its N2B nose-to-brain delivery system for biodefense and Alzheimer’s disease applications.
In exchange, Oncotelic received $12.5 million in Lunai Series B Convertible Preferred Stock, while retaining rights to develop the N2B platform for other indications such as Parkinson’s disease.
The partnership leverages Oncotelic's biodefense expertise to target government funding opportunities from agencies like BARDA and the DOD.
• 5mo ago AI analysis › Press Release
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
Oncotelic Therapeutics announced the integration of approximately 28 million scientific abstracts into its proprietary PDAOAI platform, enabling real-time application within a jointly developed robotics platform with TechForce Robotics.
The Company is advancing toward initial commercial deployment in the coming weeks, with the combined platform designed to improve efficiency and compliance in pharmaceutical development.
CEO Dr. Vuong Trieu stated that embedding scientific knowledge into robotics aims to transform drug development and production for the broader industry.
• 6mo ago AI analysis › Press Release
NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways
globenewswire.com • 6mo ago Press Release
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy
globenewswire.com • 6mo ago Press Release ⚠ 2
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
BioMedWire released an editorial profiling Oncotelic Therapeutics, citing the company as a real-world example of how scientific advancements and fair-value accounting drive biotech valuations.
The article highlights Oncotelic's 45% ownership in GMP Bio, noting that the joint venture was recently assessed at an enterprise value of more than $1 billion.
It also describes the company's focus on oncology and AI-driven drug development, supported by a patent portfolio of over 150 applications led by CEO Dr. Vuong Trieu.
• 6mo ago AI analysis › Press Release ⚠ 2
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
BioMedWire released an editorial analyzing the biotechnology sector's shift toward fair-value accounting, which allows companies to capitalize scientific progress as a balance sheet asset rather than just an expense.
The article highlights Oncotelic Therapeutics as a case study, noting its 45% stake in GMP Bio was recently assessed at over $1 billion in enterprise value.
IO Biotech is mentioned briefly in the list of industry players, with the text noting a strategic shift in 2026 to maximize value for its immune-modulatory cancer vaccines.
• 6mo ago AI analysis › Press Release ⚠ 3
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
Oncotelic Therapeutics announced its placement in a BioMedWire editorial discussing how advancing drug pipelines are driving real-time valuation in the biotech sector.
The company highlighted its 45% ownership stake in GMP Bio, which the article states was recently measured at a greater than $1 billion enterprise value.
The profile also noted that CEO Dr. Vuong Trieu has filed more than 150 patent applications and holds 39 issued U.S. patents.
• 6mo ago AI analysis › Press Release ● Major
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
globenewswire.com • 6mo ago Press Release
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
globenewswire.com • 6mo ago 
